NFKB1 and plasma cell myeloma: Proteasome inhibition in patients with multiple myeloma has an anabolic effect on bone formation (Garrett et al., 2003; Zangari et al., 2005; Terpos et al., 2007), thought to be through its effects on β‐catenin and the NF‐κB pathway (Qiang et al., 2009).